XML 73 R45.htm IDEA: XBRL DOCUMENT v3.25.4
Strategic transactions and agreements - Ayala Pharmaceuticals - Varegacestat - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
Mar. 25, 2024
Dec. 31, 2025
Dec. 31, 2024
Asset acquisitions      
Asset purchase agreement, accrued development milestone   $ 10,000 $ 6,150
Ayala Asset Purchase Agreement      
Asset acquisitions      
Upfront consideration paid to Ayala $ 20,039    
Number of shares issued 2,175,489    
Common stock issued $ 50,645    
Share price per share $ 24    
Percentage of discount related to unregistered share restrictions to be deducted from the share price 3.00%    
Consideration paid $ 71,341    
Transaction costs 657    
Development milestone amount   $ 10,000  
Ayala Asset Purchase Agreement | Maximum      
Asset acquisitions      
Payment to be made in cash $ 27,500